{"Title": "No hiding place for BOB inside myeloma", "Year": 2017, "Source": "Blood", "Volume": "129", "Issue": 10, "Art.No": null, "PageStart": 1236, "PageEnd": 1237, "CitedBy": 1, "DOI": "10.1182/blood-2017-01-761510", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85015237458&origin=inward", "Abstract": "\u00a9 2017 by The American Society of Hematology.In this issue of Blood, Jahn and colleagues have demonstrated that T-cell receptor (TCR) gene transfer can produce cytotoxic T cells that are capable of eliminating myeloma cells in vivo.1 The therapeutic TCR can equip human T cells with specificity for octamer binding protein-1 (BOB1), a transcription coactivator that is expressed in normal B cells, multiple myeloma, and B-lineage malignancies, thus providing novel options for immunotherapy of B-cell tumors that do not express CD19 or other surface antigens suitable for targeting with chimeric antigen receptor (CAR)-engineered T cells (see figure).", "AuthorKeywords": null, "IndexKeywords": ["Humans", "Multiple Myeloma", "Trans-Activators"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-85015237458", "SubjectAreas": [["Biochemistry", "BIOC", "1303"], ["Immunology", "IMMU", "2403"], ["Hematology", "MEDI", "2720"], ["Cell Biology", "BIOC", "1307"]], "AuthorData": {"57202567329": {"Name": "Stauss H.", "AuthorID": "57202567329", "AffiliationID": "60022148", "AffiliationName": "University College London"}}}